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A B S T R A C T
Background
In neovascular age-related macular degeneration, new vessels grow under the retina, distorting vision and leading to scarring. This is
further exacerbated if the blood vessels leak. Photodynamic therapy, originally used in cancer treatment, has been investigated as a way
to treat the neovascular membranes without affecting the retina.
Objectives
The aim of this review is to examine the effects of photodynamic therapy in the treatment of neovascular age-related macular degener-
ation.
Search strategy
We searched for trials in the Cochrane Central Register of Controlled Trials - CENTRAL (which includes the Cochrane Eyes and
Vision Group trials register) on the Cochrane Library (Issue 4 2002), MEDLINE (1966 to November 2002) and EMBASE (1980 to
November 2002). We used the Science Citation Index to search for reports that cited relevant study reports. We contacted experts in
the field and we searched the reference lists of relevant studies for further trial reports.
Selection criteria
We included randomised trials of photodynamic therapy in people with choroidal neovascularisation due to age-related macular
degeneration.
Data collection and analysis
Two reviewers extracted the data independently. Relative risks were combined using a fixed effect model after testing for heterogeneity
using a chi-square test.
Main results
Two published trials were identified that randomised 948 participants to verteporfin therapy compared to 5% dextrose in water. Both
trials were performed by the same investigators using largely the same clinical centres and funded by manufacturers of verteporfin.
Outcome data were available at 12 and 24 months after the first treatment. Participants received on average five treatments over two
years. The relative risk of losing three or more lines of visual acuity at 24 months comparing the intervention with the control group
was 0.77 (95% confidence interval 0.69 to 0.87). The relative risk of losing six or more lines of visual acuity at 24 months comparing
the intervention with the control group was 0.62 (95% confidence interval 0.50 to 0.76). The results at 12 months were similar to
those at 24 months.
Authors’ conclusions
Photodynamic therapy in people with choroidal neovascularisation due to age-related macular degeneration is effective in preventing
visual loss. Outcomes and potential adverse effects of this treatment should be monitored closely. Further independent trials of
Verteporfin are required to establish that the effects seen in this study are consistent and to determine important questions not yet
addressed, particularly relating to quality of life and cost.
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S Y N O P S I S
Photodynamic therapy may reduce vision loss caused by one type of age-related macular degeneration, but more research is needed
Age-related macular degeneration (AMD) affects the macula, the centre of the retina (the light-sensitive area inside the eye). One type
is called ’wet’ or neovascular AMD, as new blood vessels develop in the macula. These can leak and scar the eye, causing vision loss.
Photodynamic therapy involves injecting chemicals, then radiating light as the chemicals flow through these new blood vessels. This
aims to activate the chemicals enough to destroy the vessels, but not enough to hurt the eye. The review found evidence that this may
reduce vision loss caused by neovascular AMD, but more research is needed.
B A C K G R O U N D
Age-related macular degeneration (AMD) is a disease affecting the
macula, the central area of the retina. The disease is defined as
degeneration of the macula in older people (aged over 50) with no
other apparent cause for the degeneration.
There are several signs in the retina that are associated with in-
creasing age and increased risk of developing age-related macular
degeneration. These signs, known as age-related maculopathy, in-
clude the presence of drusen (yellow spots beneath the retina) and
pigmentary disturbance. In general age-related maculopathy is not
associated with visual loss. Some people with age-related macu-
lopathy will go on to develop age-related macular degeneration.
There are two main types of AMD. In geographic atrophy (dry)
AMD, the retinal pigment epithelium is lost completely in lo-
calised areas. In neovascular (wet) AMD, sub-retinal neovascular
membranes (new blood vessels) develop beneath the retina. These
are associated with scarring of the retina that affects vision. The
new vessels can leak causing haemorrhage that leads to larger scars
or macular oedema and significant loss of vision. This review is
concerned with treatment for neovascular age-related macular de-
generation.
Sub-retinal neovascular membranes are defined as classic or occult
according to their appearance on fluorescein angiography, in which
fluorescent dye is injected intravenously and imaged as it passes
through the blood vessels of the eye. Classic membranes are clearly
delineated and leak fluorescein uniformly. Occult membranes are
often hidden or their extent is hard to delineate, and fluorescein
leakage is patchy. It is thought that these two angiographic patterns
reflect the different extent to which the vessels have penetrated the
retinal pigment epithelium, occult vessels lying underneath the
retinal pigment epithelium. Some lesions may have both classic
and occult components.
Trials have shown that early laser photocoagulation of classic ex-
trafoveal membranes (those not directly underneath the fovea at
the centre of the macula) could delay the loss of vision in a small
number of patients (MPS 1994). However, most patients present
with subfoveal membranes, and whilst photocoagulation can limit
the extent of the subsequent visual loss, it causes immediate loss of
central vision due to the concurrent destruction of the overlying
retina.
Photodynamic therapy, originally used in the treatment of cancer,
has been investigated as a way to treat the neovascular membranes
without affecting the retina. Photoreactive chemicals are injected
into the patient and irradiated with light as they pass through the
neovascular membranes. This light is strong enough to activate
the chemicals, causing them to emit free radicals that destroy the
blood vessels, but is not strong enough to cause damage to the
overlying retina.
O B J E C T I V E S
The aim of this review is to examine the effects of photodynamic
therapy in the treatment of neovascular age-related macular de-
generation.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
We included randomised controlled trials.
Types of participants
We included trials in which participants were people with neo-
vascular age-related macular degeneration as defined by the study
investigators.
Types of intervention
We included any study in which photodynamic therapy was com-
pared to another treatment, placebo or no treatment.
Types of outcome measures
The primary outcome for this review is prevention of visual loss.
Any well-defined outcome based on visual acuity was used de-
pending on the way in which authors presented trial data. Other
validated measures of visual loss, such as contrast sensitivity, were
used where available.
The secondary outcomes for this review are:
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• new vessel growth,
• quality of life measures - any validated measurement scale which
aims to measure the impact of visual function loss on quality of
life of participants,
• any adverse outcomes as reported in trials.
S E A R C H S T R A T E G Y F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Eyes and Vision Group search strategy
Trials were identified from the Cochrane Central Register of
Controlled Trials - CENTRAL (which contains the Cochrane
Eyes and Vision Group trials register) on the Cochrane Library,
MEDLINE and EMBASE.
The following strategy was used to search CENTRAL Issue 4
2002:
#1 MACULAR-DEGENERATION:ME
#2 RETINAL-DEGENERATION:ME
#3 NEOVASCULARIZATION-PATHOLOGIC*:ME
#4 ((((((MACULA or MACULAR) or RETINA) or RETINAL)
or CHOROID) or CHOROIDAL) near (DEGENERATION
or NEOVASCULARIZATION))
#5 MACULOPATHY
#6 ((((#1 or #2) or #3) or #4) or #5)
#7 PHOTOCHEMOTHERAPY*:ME
#8 PHOTOSENSITIZING-AGENTS*:ME
#9 (((((PHOTOSENSITIZING or PHOTOSENSITISING)
or PHOTODYNAMIC) or PDT) or VERTEPORFIN) or
VISUDYNE)
#10 ((#7 or #8) or #9)
#11 (#6 and #10)
The following was used to search MEDLINE on SilverPlatter to
November 2002:
#1 “MACULAR-DEGENERATION”/ all subheadings
#2 “RETINAL-DEGENERATION”/ all subheadings
#3 “CHOROIDAL-NEOVASCULARIZATION”/ all
subheadings
#4 ((MACUL* or RETINA* or CHOROID*) near
(DEGENER* or NEOVASC*)) in TI,AB
#5 MACULOPATHY in TI,AB
#6 #1 or #2 or #3 or #4 or #5
#7 explode “PHOTOCHEMOTHERAPY”/ all subheadings
#8 explode “PHOTOSENSITIZING-AGENTS”/ all
subheadings
#9 (PHOTOSENSITI?ING?AGENTS or
’PHOTOSENSITI?ING AGENTS’ or PORPHYRIN* or
BENZOPORPHYRIN) in NM,TI,AB
#10 (PHOTODYNAMIC or PDT) in TI,AB
#11 VERTEPORFIN or VISUDYNE in TI,AB
#12 #7 or #8 or #9 or #10 or #11
#13 #6 and #12
To identify randomised controlled trials, this search was
combined with the Cochrane Highly Sensitive Search Strategy
phases one and two as contained in the Cochrane Reviewers’
Handbook (Clarke 2000).
The following strategy was used to search EMBASE on
SilverPlatter to November 2002:
#1 explode “RETINA-MACULA-DEGENERATION”/ all
subheadings
#2 “RETINA-DEGENERATION”/ all subheadings
#3 “NEOVASCULARIZATION-(PATHOLOGY)”/ all
subheadings
#4 “SUBRETINAL-NEOVASCULARIZATION”/ all
subheadings
#5 ((MACUL* or RETINA* or CHOROID*) near
(DEGENER* or NEOVASC*)) in TI,AB
#6 MACULOPATHY in TI,AB
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 “PHOTODYNAMIC-THERAPY”/ all subheadings
#9 explode “PHOTOSENSITIZING-AGENT”/ all subheadings
#10 (PHOTODYNAMIC or PDT) in TI,AB
#11 (PHOTOSENSITI?ING AGENT* or VERTEPORFIN or
VISUDYNE) in RN,TI,AB
#12 #8 or #9 or #10 or #11
#13 #7 and #12
To identify randomised controlled trials, this search was
combined with the following search:
#1 “RANDOMIZED-CONTROLLED-TRIAL”/ all
subheadings
#2 “RANDOMIZATION”/ all subheadings
#3 “CONTROLLED-STUDY”/ all subheadings
#4 “MULTICENTER-STUDY”/ all subheadings
#5 “PHASE-3-CLINICAL-TRIAL”/ all subheadings
#6 “PHASE-4-CLINICAL-TRIAL”/ all subheadings
#7 “DOUBLE-BLIND-PROCEDURE”/ all subheadings
#8 “SINGLE-BLIND-PROCEDURE”/ all subheadings
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#10 (RANDOM* or CROSS?OVER* or FACTORIAL* or
PLACEBO* or VOLUNTEER*) in TI,AB
#11 (SINGL* or DOUBL* or TREBL* or TRIPL*) near
(BLIND* or MASK*) in TI,AB
#12 #9 or #10 or #11
#13 HUMAN in DER
#14 (ANIMAL or NONHUMAN) in DER
#15 #13 and #14
#16 #14 not #15
#17 #12 not #16
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We used the Science Citation Index to search for reports that
cited relevant study reports. We contacted experts in the field for
information about further trials, and we searched the reference
lists of relevant studies for further trial reports.
M E T H O D S O F T H E R E V I E W
Selection of trials
Two reviewers independently scanned the titles and abstracts
resulting from the electronic searches. We obtained full copies of
all potentially or definitely relevant articles. Two reviewers assessed
the full copies according to the ’Criteria for considering studies
for this review’. Only articles meeting these criteria were assessed
for quality.
Assessment of methodological quality
Two reviewers independently assessed study quality according
to methods set out in Section 6 of the Cochrane Reviewers’
Handbook. Reviewers were not masked to any trial details during
the assessment. Four parameters of quality were considered:
allocation concealment and method of allocation to treatment,
masking of providers and recipients of care, masking of outcome
assessment, and completeness of follow-up. Each parameter of trial
quality was graded: A - adequate; B - unclear; C - inadequate.
Disagreement between the reviewers on assessments was resolved
by discussion. We contacted the trial authors for clarification on
any parameter graded B - unclear, and we excluded any trial scoring
C - inadequate on allocation concealment.
Data collection
Two reviewers independently extracted data using a form
developed by the Cochrane Eyes and Vision Group (available from
the editorial base). We resolved discrepancies by discussion. Two
reviewers independently entered data into RevMan 4.1 and we
checked any inconsistencies between the two against the study
report.
Data synthesis
Our original data analysis plan was to summarise data from studies
collecting similar outcome measures with similar follow-up times
using the Peto method, after testing for heterogeneity between
trial results using a standard chi-square test. The main outcome
analysed, loss of three or more lines of visual acuity at 12 and
24 months follow-up, occurred relatively frequently in the trial
cohort. The odds ratio, therefore, does not approximate to the
relative risk. We present relative risks in this review. We planned
to conduct sensitivity analyses to determine the effect of excluding
studies given a grade of C - inadequate on any parameter of quality,
but to date this has not been necessary.
D E S C R I P T I O N O F S T U D I E S
The original electronic searches identified 76 reports. We found
one randomised controlled trial (TAP 1999). Since the searches
were updated in February 2001, May 2002 and January 2003, one
further study has been identified and is included in this review
(VIP 2001).
The TAP 1999 study was a multicentre study investigating the
safety and effectiveness of verteporfin (Visudyne; CIBA Vision
Corp, USA). It was conducted in 22 ophthalmology practices in
Europe and North America. Participants were people with sub-
foveal choroidal neovascularisation (CNV) caused by age-related
macular degeneration. The majority of participants were white
(98%) with a mean age of 75 years. The VIP 2001 study was very
similar to the TAP 1999 study. It was conducted in 28 practices,
most of whom had also participated in the TAP 1999 study. As
for the TAP 1999 study, the majority of participants were white
(98%) with a mean age of 75 years.
In both trials, verteporfin (six milligrams per square metre of body
surface area) was compared to placebo (5% dextrose in water)
administered via intravenous infusion of 30 millilitres over 10
minutes. This was followed after 15 minutes by application of
83 seconds of laser light at 689 nm delivered 50 joules/square
centimetre (cm²) at an intensity of 600 mW/cm² using a spot
size with a diameter 1000 microns larger than the greatest linear
dimension of the CNV lesion.
Participants in the TAP 1999 trial were reviewed every three
months when visual acuity was measured and repeat fluorescein
angiography performed. If the trial surgeon judged a recurrence
of the membrane to be present or a persistence of the previous
lesion, then repeat treatment was undertaken. In the phase one
and two studies, it was concluded that up to five treatments were
necessary to stabilise the situation (Miller 1999; Schmidt-Erfurth
1999). In the first year, a mean of 3.4 treatments were delivered to
the treatment group and 3.7 to the control group. In the second
year, a mean of 2.2 treatments were delivered to the treatment
group and 2.8 to the controls group.
Visual acuity was measured in the VIP 2001 trial at 12 and 24
months. The report of the study did not indicate the mean num-
ber of treatments delivered for all participants. However, in the
subgroup with occult CNV (76% of all participants) 3.1 treat-
ments were given in the treatment group and 3.5 in the control
group. In the second year, 1.8 and 2.4 treatments were given in
the verteporfin and control groups respectively.
TAP 1999 was originally devised as two concurrent trials in order
to comply with regulatory agency requirements. The study pro-
tocols were identical. Ten of the clinical centres were assigned to
study A and 12 to study B. As the results of the trials were similar
and the investigators analysed and presented the data as one trial,
we have also assessed it as one trial.
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M E T H O D O L O G I C A L Q U A L I T Y
Both TAP 1999 and VIP 2001 were high quality studies with a
very similar study design.
Allocation of treatment group was by opaque serially numbered
sealed envelopes and was stratified by clinical centre. The baseline
characteristics of the participants by treatment group were pub-
lished. The groups were well balanced with respect to a variety of
demographic and clinical variables. Only one eye per person was
treated.
Reasonable attempts were made to mask the ophthalmologist, par-
ticipant, vision examiner and Photograph Reading Center per-
sonnel to the treatment assigned. As verteporfin and placebo were
different colours (green versus colourless), the solutions and the
intravenous tubing were covered with foil. The fundus appearance
does not change during treatment to indicate whether verteporfin
or placebo had been infused. There is no other physical evidence
of treatment as verteporfin dye is excreted in the faeces and does
not cause any colour change, and does not alter the colour of
the skin or urine. It was therefore unlikely that participants were
aware of their treatment status. In TAP 1999 the study investiga-
tors reported two instances where the participants were unmasked,
and four cases where the ophthalmologists were unmasked, having
noted a green solution.
Rates of follow-up were high in both studies. In TAP 1999 94%
were seen at 12 months and 87% at 24 months. Follow-up was
similar between the two treatment groups. The analysis was inten-
tion-to-treat and subgroup analyses were planned a priori (Bressler
N, personal communication). In VIP 2001 93% were seen at 12
months and 86% at 24 months. All participants were included in
the analyses and missing values were imputed using the method
of last observation carried forward.
R E S U L T S
The realistic aim of photodynamic therapy is to slow progression
of age-related macular degeneration, not to produce normal vi-
sion. Outcomes are therefore expressed as risks of a poor outcome,
rather than as improvements in vision. All results are based on
the comparison of people randomised to receive verteporfin with
those randomised to receive placebo (control).
OVERALL ANALYSIS
Loss of three or more lines of visual acuity
A total of 948 patients from TAP 1999 and VIP 2001 studies were
included in the meta-analysis. At 12 months, the pooled relative
risk of losing three or more lines of visual acuity was 0.80 (95%
confidence interval (CI) 0.70 to 0.91). The relative risk reduction
was therefore 0.20 (95% CI 0.09 to 0.30). This analysis was done
using a fixed effect model. A random effects model gave a non-
significant result, largely because it placed more weight on the VIP
study (pooled relative risk 0.82 (95% CI 0.64 to 1.04).
At 24 months, the pooled relative risk was 0.77 (95% CI 0.69 to
0.87) and the relative risk reduction was therefore 0.23 (95% CI
0.13 to 0.31). The random effects model gave a similar result.
Loss of six or more lines of visual acuity
At 12 months, the relative risk of losing six or more lines of visual
acuity was 0.62 (95% CI 0.44 to 0.87) (TAP 1999 study only, data
not reported for VIP 2001 study). The relative risk reduction was
therefore 0.38 (95% CI 0.13 to 0.56). At 24 months, the pooled
relative risk was 0.62 (95% CI 0.50 to 0.76) and the relative risk
reduction was therefore 0.38 (95% CI 0.24 to 0.50).
Mean number of lines lost
In the TAP 1999 the mean number of lines of vision lost at 12
months was 2.2 in the intervention group and 3.5 in the control
group. The difference was 1.3 with fewer lines lost in the inter-
vention group. The P value for the difference in the mean number
of lines lost was reported as P < 0.001 (Wilcoxon rank sum test).
At 24 months, the mean number of lines of vision lost was 2.7 in
the intervention group and 3.9 in the control group, a difference
of 1.2 lines (P < 0.001).
The standard deviations for the mean numbers of lines lost were
not reported and we therefore could not calculate confidence in-
tervals.
Data on mean number of lines lost for the whole VIP 2001 study
group was not reported.
SUBGROUP ANALYSES
Subgroup data are available only for the outcome ’loss of three or
more lines of visual acuity’ in the TAP 1999 study but for both
outcomes (loss of three lines and loss of six lines) in the VIP 2001
study.
Evidence of occult choroidal neovascularisation
In the TAP 1999 study the relative risks of losing three or more
lines of visual acuity at 12 months were 0.90 if occult choroidal
neovascularisation (CNV) was present (95% CI 0.73 to 1.11) and
0.34 if occult CNV was absent (95% CI 0.22 to 0.51). At 24
months, the relative risks were 0.88 (95% CI 0.74 to 1.04) and
0.42 (95% CI 0.30 to 0.60) respectively.
The test for effect modification between these two subgroups was
significant. Neither the 95% confidence intervals, nor the 99%
confidence intervals, for these two subgroups overlap.
Lesion area composed of classic choroidal neovascularisation
In the TAP 1999 study, the proportion of the lesion comprised of
classic CNV was estimated as 0%; greater than 0% but less than
50%; greater than 50%. The proportion was unknown in four
participants (three in the treatment group and one in the control
group). The subgroup analyses were therefore based on a total of
399 eyes.
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In the VIP 2001 study, the majority of the participants (76%) had
“occult with no classic CNV”. An additional 56 eyes had some
classic CNV (less than 50% but greater than 0% as above). Only
19 eyes had predominantly classic CNV.
The pooled relative risks for losing three or more lines of visual
acuity at 12 months for the group with 0% CNV was 0.84 (95%
CI 0.68 to 1.04). Results for three or more lines lost at 12 months
were not reported for the other two subgroups in the VIP 2001
study. The results for the TAP 1999 study were as follows. The
relative risk for losing three or more lines of visual acuity at 12
months in people with 0% but less than 50% CNV was 0.99 (95%
CI 0.76 to 1.29) and 0.54 for greater than 50% (95% CI 0.40 to
0.71).
At 24 months the pooled relative risks for losing three or more
lines of visual acuity were: 0.77 (95% CI 0.64 to 0.92), 0.93 (95%
CI 0.77 to 1.14) and 0.60 (95% CI 0.48 to 0.75) respectively.
These results suggest there was a reduction in the risk of loss of
vision when classic CNV was absent or when greater than 50%
of the lesion was comprised of classic CNV. However there was
very little reduction in risk when between 0% and 50% of the
lesion was comprised of classic CNV. However the test for effect
modification between these three subgroups was not statistically
significant (p=0.066).
NUMBERS NEEDED TO TREAT
We calculated the numbers needed to treat (NNTs) to prevent
one person losing three or more lines and, where possible, one
person losing six or more lines of vision. These NNTs are derived
from the study population, that is, people with subfoveal CNV
and a baseline visual acuity of between 20/40 and 20/200 with
approximately 5 treatments over two years.
The NNT to prevent one person losing three or more lines of
vision at 24 months was 7.1 (95% CI 4.8 to 12.5). The NNT to
prevent one person losing six or more lines of vision at 24 months
was 7.1 (95% CI 5.0 to 12.5).
ADVERSE EFFECTS
Reports of visual disturbance (reports of “abormal vision”, “de-
creased vision” and visual field defect) occurred in one in every
four people taking part in the TAP 1999 and VIP 2001 studies.
This is perhaps unsurprising as participants had neovascular AMD.
However, people treated with verteporfin were more likely to re-
port visual disturbance (pooled relative risk 1.61, 95% CI 1.24 to
2.09). Presumably this visual disturbance must have been reason-
ably transient as visual outcomes at 12 and 24 months were better
in the treatment group. 2.4% of people treated with verteporfin
experienced infusion-related back pain and 2.4% had photosensi-
tivity reactions. Problems with the injection site occurred in 13.1%
of people treated with verteporfin compared to 5.6% people in
the control group. Few allergic reactions were seen and these were
equally likely in treatment and control groups.
D I S C U S S I O N
The absence to date of any effective treatment for neovascular age-
related macular degeneration (except for the few in whom laser
photocoagulation works) means that there will be intense inter-
est in photodynamic therapy for the many millions of sufferers
of the disease worldwide. Unfortunately, photodynamic therapy,
like photocoagulation, can only be effective during the prolifera-
tive stage of the disease while the neovascular process is active. It
cannot have any effect once sight is lost and the scarring process is
complete. Therefore, like so many other degenerative processes of
the neuroretina, nothing can be done to restore function once the
damage is done. Most sufferers of the condition have established
sight loss and, for these, the publicity surrounding the launch of
Visudyne (verteporfin) will have raised false hopes. However, this
review indicates that for people with active neovascular disease,
photodynamic therapy can prevent vision loss.
A key question is how long the effect of treatment will last and
whether repeated treatments would be required in the longer term.
This review indicates that treatment benefits last for at least two
years. An open-label extension of the TAP 1999 study indicated
that vision outcomes remained relatively stable from 24 to 48
months(TAP 2002).
Another important issue is how many presenting patients will ben-
efit from photodynamic therapy. In addition to the problem of
accessing specialist services in time, there is the question of the
proportion of lesions that will actually be treatable. The evidence
reported here clearly suggests that purely classic neovascular mem-
branes do well. Subgroup analysis of the TAP 1999 study suggested
that photodynamic therapy is not effective when occult CNV is
present. Occult vessels mean that the extent of the membrane can-
not be clearly defined and so it is not surprising that treatment
is found to be less effective because the laser cannot be aimed
at the entire membrane. However, the VIP 2001 study recruited
mostly patients with occult neovascularisation and demonstrated a
treatment benefit of photodynamic therapy at 12 and 24 months.
Pooled analysis of the TAP 1999 and VIP 2001 studies in this
review showed no statistically significant difference in treatment
effects in subgroups defined by the presence or absence of classic
CNV.
We are not told in the available reports the extent to which clini-
cians and indeed the trial Photograph Reading Center personnel
were able to agree about the subgroup classification of classic or
occult lesions. It is likely that there is much variation in opinion
on this. The necessary skill to report on fluorescein angiograms
and recognise different lesion types is highly refined. Most experts
assert that stereo images are required to be able to locate the posi-
tion in depth of staining or fluorescein leaks. Stereophotography
requires either a dedicated camera equipped to take simultaneous
stereo images or a skilled photographer who takes sequential im-
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ages slightly laterally displaced from one another, providing a non-
simultaneous or pseudo-stereo image.
The natural history of the growth of sub-retinal membranes varies
from individual to individual. They may be aggressive and rapidly
growing or indolent. This is the kind of individual factor that
will influence the likelihood of a patient being in a position to
benefit from this treatment. The trial report does not comment
on the proportion of participants presenting to the trial centres
that had treatable lesions. The verbal estimate from one trialist
was approximately 25%, and of another expert, between 5% and
7%. This is of crucial importance in estimating the impact of this
new treatment on health care budgets.
Age-related macular degeneration is a bilateral disease although
one eye is usually affected before the other. With a lesion present in
one eye, the annual cumulative incidence of a lesion in the second
eye is estimated to be about 15%. Clinicians now commonly advise
patients with a lesion in one eye to be watchful for the onset
of symptoms in the second eye, and to present as soon as those
symptoms are noticed to improve the chances of catching the
lesion in the second eye in time. This often entails the provision of
an Amsler grid, a simple chart on which a number of gridlines are
printed around a central fixation spot. The patient is instructed to
examine the grid and to look for focal distortion of the lines in the
grid which would indicate local elevation of the retina as a result
of the growth of an underlying membrane. This strategy offers the
best hope of saving sight with this new treatment at least in places
where access to a qualified ophthalmologist can be slow.
It should also be recalled that this treatment does not restore sight
but rather, prevents further deterioration. Sustaining numerous
assessments which involve relative invasive treatments may have
an adverse effect on the patient. Without patient orientated out-
comes in this trial, we cannot comment on the patient’s perspec-
tive on the experience of Visudyne therapy. It is likely that in most
cases, especially where loss of sight of the second eye is threatened,
patients will be willing to undergo all the necessary interventions,
even when the probability of success is small.
Adverse effects occurred infrequently with the exception of the
rather vague “visual disturbance” which affected more people in
the verteporfin group compared to the control group. However,
this was not reflected in the visual acuity outcomes. Infusion-
related back pain occurred in 2.4% which is substantially lower
than in some other studies. For example, in a series of 250 people
treated with verteporfin 9.6% experienced verteporfin associated
pain, most of which was back pain (Borodoker 2002).
The trials included in this review appear to have been performed
to high standards and were closely supervised by the Food and
Drugs Administration of the USA. Both trials were sponsored by
the manufacturers of the drug (CIBA Vision & Novartis Oph-
thalmics) and declared potential conflicts of interest exist for a
number of the trialists who hold interests in the manufacturer of
the laser technology. This makes detailed scrutiny of reports of the
trial essential. Of concern are the numerous protocol revisions that
were registered with the Institutional Review Bodies throughout
the study and after completion of follow-up. Although we have
not yet had access to the main protocol or to the revisions, a CIBA
representative has assured us that the changes were not substan-
tive and, in particular, that there were no changes to the a priori
determinants of the primary outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review provides evidence that photodynamic therapy in peo-
ple with classic and occult choroidal neovascularisation due to age-
related macular degeneration is effective in preventing visual loss.
Approximately seven people need to be treated with approximately
five treatments over two years to prevent one person losing three
or more lines of visual acuity.
Two trials were included in this review. Both trials were performed
by the same investigators using largely the same clinical centres and
funded by manufacturers of verteporfin. As for all new technology,
outcomes and potential adverse effects need to be monitored when
introduced into clinical practice.
There are major implications for health services, both in terms
of potential expenditure and organisation, if photodynamic ther-
apy is to be introduced. Where referral to an ophthalmologist is
through a primary care network, facilities for the recognition of
this condition in its early stages are needed. There is potential for
an enormous increase in referral of people with early age-related
maculopathy for assessment, in case an early treatable lesion is
present. This could swamp already overstretched facilities at the
secondary care level. Extra resources will be required at the sec-
ondary care level to manage increased referrals, for the necessary
technology to diagnose treatable lesions and to deliver treatment.
Implications for research
Two trials were included in this review. Both trials were performed
by the same investigators using largely the same clinical centres
and funded by manufacturers of verteporfin.
Further independent trials of verteporfin are required to establish
that the effects seen in this study are consistent and to determine
important questions not yet addressed - particularly relating to
quality of life and cost. Descriptive epidemiology on the popula-
tion at risk and the numbers likely to benefit is essential to estimate
the impact of this new treatment on health service resources. We
need to establish how people in need of treatment can access it in
time. Surveillance for possible rare but severe adverse effects will
be required.
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T A B L E S
Characteristics of included studies
Study TAP 1999
Methods Randomised controlled trial: one eye per patient was randomised in a 2:1 (treatment:control) ratio
Participants 609 people with subfoveal CNV lesions caused by AMD with evidence of classic CNV and best corrected
acuity of approximately 20/40 to 20/200
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy following intravenous
5% dextrose
Outcomes Visual acuity at 12 and 24 months
Notes
Allocation concealment A
Study VIP 2001
Methods Randomised controlled trial: one eye per patient was enrolled. Randomisation in sealed envelopes stratified
by clinical centre.
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Characteristics of included studies (Continued )
Participants 339 people with subfoveal CNV caused by AMD
Interventions Photodynamic therapy following verteporfin injection versus photodynamic therapy following intravenous
5% dextrose
Outcomes Visual acuity at 12 and 24 months
Secondary outcomes include contrast sensitivity and changes in angiographic outcomes
Notes Randomised 2:1 to verteporfin treatment
Allocation concealment A
AMD - age-related macular degeneration
CNV - choroidal neovascularisation
Characteristics of excluded studies
Schmidt-Erfurth 1999 Non randomised open-label phase I and II trial
Characteristics of ongoing studies
Study ADD-V
Trial name or title Addition of an anti-inflammatory called Voltaren Ophthalmic®
Participants
Interventions
Outcomes
Starting date
Contact information
Notes
Study Japan
Trial name or title Visudyne for CNV due to AMD
Participants
Interventions
Outcomes
Starting date Results expected at end 2003
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
Study VALIO
Trial name or title Altered light treatment using delayed light after Visudyne in occult AMD
Participants
Interventions
Outcomes
Starting date
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
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Characteristics of ongoing studies (Continued )
Study VER
Trial name or title Visudyne in Early Retreatment Phase IIIB clinical trial
Participants People with predominantly classic CNV
321 people at 31 sites enrolled
Interventions Visudyne therapy every 3 months (standard) vs more frequent regiment
Outcomes
Starting date Results expected at end 2003
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
Study VIM
Trial name or title Visudyne in Minimally Classic study
Participants
Interventions Visudyne therapy vs visudyne therapy with reduced light intensity vs placebo
Outcomes
Starting date
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
Study VIO
Trial name or title Visudyne therapy in Occult Phase III trial
Participants People with occult but no classic CNV due to AMD
Interventions
Outcomes
Starting date
Contact information Nic Gwatkin, Head of Marketing, Novartis Ophthalmics
Notes
G R A P H S
Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Overall effect: >=3 lines lost at
12 mths
2 948 Relative Risk (Fixed) 95% CI 0.80 [0.70, 0.91]
02 Overall effect: >=3 lines lost at
24 mths
2 948 Relative Risk (Fixed) 95% CI 0.77 [0.69, 0.87]
03 Overall effect: >=6 lines lost at
12 mths
Relative Risk (Fixed) 95% CI Totals not selected
04 Overall effect: >=6 lines lost at
24 mths
2 948 Relative Risk (Fixed) 95% CI 0.62 [0.50, 0.76]
05 Classic CNV subgroups: >=3
lines lost at 12 mths
Relative Risk (Fixed) 95% CI Subtotals only
06 Classic CNV subgroups: >=3
lines lost at 24 mths
6 942 Relative Risk (Fixed) 95% CI 0.77 [0.69, 0.87]
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07 Adverse effects: Visual
disturbance
2 948 Relative Risk (Fixed) 95% CI 1.61 [1.24, 2.09]
08 Adverse effects: Injection site 2 948 Odds Ratio (Fixed) 95% CI 2.54 [1.50, 4.31]
09 Adverse effects: Infusion-
related back pain
2 948 Odds Ratio (Fixed) 95% CI 8.40 [1.11, 63.58]
10 Adverse effects: Allergic
reactions
2 948 Odds Ratio (Fixed) 95% CI 0.94 [0.34, 2.56]
11 Adverse effects: Photosensitivity
reactions
2 948 Odds Ratio (Fixed) 95% CI 5.37 [1.01, 28.60]
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G R A P H S A N D O T H E R T A B L E S
Fig. 1. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.01 Overall effect: >=3 lines lost at 12 mths
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 01 Overall effect: >=3 lines lost at 12 mths
Study Treatment Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 156/402 111/207 64.0 0.72 [ 0.61, 0.86 ]
VIP 2001 114/225 62/114 36.0 0.93 [ 0.75, 1.15 ]
Total (95% CI) 627 321 100.0 0.80 [ 0.70, 0.91 ]
Total events: 270 (Treatment), 173 (Placebo)
Test for heterogeneity chi-square=3.23 df=1 p=0.07 I?? =69.0%
Test for overall effect z=3.26 p=0.001
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
Fig. 2. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.02 Overall effect: >=3 lines lost at 24 mths
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 02 Overall effect: >=3 lines lost at 24 mths
Study Treatment Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 189/402 129/207 62.8 0.75 [ 0.65, 0.88 ]
VIP 2001 121/225 76/114 37.2 0.81 [ 0.68, 0.96 ]
Total (95% CI) 627 321 100.0 0.77 [ 0.69, 0.87 ]
Total events: 310 (Treatment), 205 (Placebo)
Test for heterogeneity chi-square=0.32 df=1 p=0.57 I?? =0.0%
Test for overall effect z=4.41 p=0.00001
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
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Fig. 3. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.03 Overall effect: >=6 lines lost at 12 mths
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 03 Overall effect: >=6 lines lost at 12 mths
Study Treatment Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
TAP 1999 59/402 49/207 0.62 [ 0.44, 0.87 ]
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
Fig. 4. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.04 Overall effect: >=6 lines lost at 24 mths
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 04 Overall effect: >=6 lines lost at 24 mths
Study Treatment Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 73/402 62/207 53.3 0.61 [ 0.45, 0.81 ]
VIP 2001 67/225 54/114 46.7 0.63 [ 0.48, 0.83 ]
Total (95% CI) 627 321 100.0 0.62 [ 0.50, 0.76 ]
Total events: 140 (Treatment), 116 (Placebo)
Test for heterogeneity chi-square=0.03 df=1 p=0.86 I?? =0.0%
Test for overall effect z=4.65 p<0.00001
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
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Fig. 5. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.05 Classic CNV subgroups: >=3 lines lost at 12 mths
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 05 Classic CNV subgroups: >=3 lines lost at 12 mths
Study Treatment Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 No classic CNV
TAP 1999 14/38 13/19 100.0 0.54 [ 0.32, 0.90 ]
Subtotal (95% CI) 38 19 100.0 0.54 [ 0.32, 0.90 ]
Total events: 14 (Treatment), 13 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=2.35 p=0.02
02 Classic CNV > 0 to < 50%
TAP 1999 89/202 46/103 100.0 0.99 [ 0.76, 1.29 ]
Subtotal (95% CI) 202 103 100.0 0.99 [ 0.76, 1.29 ]
Total events: 89 (Treatment), 46 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.10 p=0.9
03 Classic CNV > 50% (predominantly classic)
TAP 1999 52/159 51/84 100.0 0.54 [ 0.41, 0.71 ]
Subtotal (95% CI) 159 84 100.0 0.54 [ 0.41, 0.71 ]
Total events: 52 (Treatment), 51 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=4.31 p=0.00002
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
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Fig. 6. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.06 Classic CNV subgroups: >=3 lines lost at 24 mths
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 06 Classic CNV subgroups: >=3 lines lost at 24 mths
Study Treatment Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 No classic CNV
TAP 1999 18/41 14/20 7.0 0.63 [ 0.40, 0.98 ]
VIP 2001 91/166 63/92 30.0 0.80 [ 0.66, 0.97 ]
Subtotal (95% CI) 207 112 37.0 0.77 [ 0.64, 0.92 ]
Total events: 109 (Treatment), 77 (Placebo)
Test for heterogeneity chi-square=0.95 df=1 p=0.33 I?? =0.0%
Test for overall effect z=2.89 p=0.004
02 Classic CNV > 0 to < 50%
TAP 1999 106/202 58/104 28.4 0.94 [ 0.76, 1.17 ]
VIP 2001 19/38 10/18 5.0 0.90 [ 0.53, 1.52 ]
Subtotal (95% CI) 240 122 33.4 0.93 [ 0.77, 1.14 ]
Total events: 125 (Treatment), 68 (Placebo)
Test for heterogeneity chi-square=0.02 df=1 p=0.88 I?? =0.0%
Test for overall effect z=0.66 p=0.5
03 Classic CNV > 50% (predominantly classic)
TAP 1999 65/159 57/83 27.7 0.60 [ 0.47, 0.75 ]
VIP 2001 10/16 3/3 1.9 0.63 [ 0.43, 0.91 ]
Subtotal (95% CI) 175 86 29.6 0.60 [ 0.48, 0.75 ]
Total events: 75 (Treatment), 60 (Placebo)
Test for heterogeneity chi-square=0.06 df=1 p=0.81 I?? =0.0%
Test for overall effect z=4.54 p<0.00001
Total (95% CI) 622 320 100.0 0.77 [ 0.69, 0.87 ]
Total events: 309 (Treatment), 205 (Placebo)
Test for heterogeneity chi-square=10.36 df=5 p=0.07 I?? =51.7%
Test for overall effect z=4.41 p=0.00001
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours placebo
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Fig. 7. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.07 Adverse effects: Visual disturbance
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 07 Adverse effects: Visual disturbance
Study Treatment Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 89/402 32/207 55.0 1.43 [ 0.99, 2.07 ]
VIP 2001 94/225 26/114 45.0 1.83 [ 1.26, 2.66 ]
Total (95% CI) 627 321 100.0 1.61 [ 1.24, 2.09 ]
Total events: 183 (Treatment), 58 (Control)
Test for heterogeneity chi-square=0.85 df=1 p=0.36 I?? =0.0%
Test for overall effect z=3.59 p=0.0003
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Fig. 8. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.08 Adverse effects: Injection site
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 08 Adverse effects: Injection site
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 64/402 12/207 64.5 3.08 [ 1.62, 5.84 ]
VIP 2001 18/225 6/114 35.5 1.57 [ 0.60, 4.06 ]
Total (95% CI) 627 321 100.0 2.54 [ 1.50, 4.31 ]
Total events: 82 (Treatment), 18 (Control)
Test for heterogeneity chi-square=1.34 df=1 p=0.25 I?? =25.1%
Test for overall effect z=3.46 p=0.0005
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Fig. 9. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.09 Adverse effects: Infusion-related back pain
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 09 Adverse effects: Infusion-related back pain
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 10/402 0/207 49.8 11.10 [ 0.65, 190.40 ]
VIP 2001 5/225 0/114 50.2 5.71 [ 0.31, 104.21 ]
Total (95% CI) 627 321 100.0 8.40 [ 1.11, 63.58 ]
Total events: 15 (Treatment), 0 (Control)
Test for heterogeneity chi-square=0.10 df=1 p=0.75 I?? =0.0%
Test for overall effect z=2.06 p=0.04
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Fig. 10. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.10 Adverse effects: Allergic reactions
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 10 Adverse effects: Allergic reactions
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 8/402 3/207 49.7 1.38 [ 0.36, 5.26 ]
VIP 2001 3/225 3/114 50.3 0.50 [ 0.10, 2.52 ]
Total (95% CI) 627 321 100.0 0.94 [ 0.34, 2.56 ]
Total events: 11 (Treatment), 6 (Control)
Test for heterogeneity chi-square=0.90 df=1 p=0.34 I?? =0.0%
Test for overall effect z=0.13 p=0.9
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Fig. 11. Comparison 01. PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
01.11 Adverse effects: Photosensitivity reactions
Review: Photodynamic therapy for neovascular age-related macular degeneration
Comparison: 01 PHOTODYNAMIC THERAPY WITH VERTEPORFIN VERSUS PLACEBO
Outcome: 11 Adverse effects: Photosensitivity reactions
Study Treatment Control Odds Ratio (Fixed) Weight Odds Ratio (Fixed)
n/N n/N 95% CI (%) 95% CI
TAP 1999 14/402 0/207 32.5 15.49 [ 0.92, 260.96 ]
VIP 2001 1/225 1/114 67.5 0.50 [ 0.03, 8.14 ]
Total (95% CI) 627 321 100.0 5.37 [ 1.01, 28.60 ]
Total events: 15 (Treatment), 1 (Control)
Test for heterogeneity chi-square=3.32 df=1 p=0.07 I?? =69.9%
Test for overall effect z=1.97 p=0.05
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